Pandemic Flu Vaccine May Help Reduce Otitis Media Risk

Daniel Weiss, Senior Editor
Published Online: Wednesday, October 31, 2012
Follow Pharmacy_Times:
A study found significantly reduced rates of all otitis media and otitis media with effusion in children who received the H1N1 pandemic flu vaccine.

Children who received the H1N1 pandemic influenza vaccine were significantly less likely to develop otitis media (OM), according to the results of a study published online on September 30, 2012, in the European Journal of Pediatrics.
 
The researchers conducted a randomized, prospective, single-blind study in healthy children in Turkey aged 6 to 60 months during the 2009-2010 H1N1 flu pandemic. The study included 46 participants (mean age 27.83 months) who received the H1N1 flu vaccine and 46 aged-matched, unvaccinated controls (mean age 28.26 months). Participants underwent otoscopic and tympanometric evaluation twice within a 4- to 8-week follow-up period.
 
In the vaccinated group, 6.5% of participants presented with acute otitis media (AOM), 23.9% presented with otitis media with effusion (OME), and 26.1% presented with any OM. In the unvaccinated group, 17.4% presented with AOM, 26.1% presented with OME, and 39.1% presented with any OM.
 
Based on multivariate analysis to calculate risk factors for OME, AOM, and OM, the researchers found that unvaccinated children had 2.9 times the risk for OME and OM compared with vaccinated children, a statistically significant result. Unvaccinated children also had 9.5 times the risk for AOM compared with vaccinated children, although this result was not statistically significant. Other factors associated with increased risk of developing OM included male gender and bottle feeding or using a pacifier.

Related Articles
Doctors Without Borders says virus cannot be contained without massive mobilization of resources to West Africa.
Ebola-related death toll climbs above 1200 as health care workers face increased threats from desperate region.
In a large-scale trial, Sanofi’s Fluzone High-Dose vaccine demonstrated efficacy in preventing influenza specifically in adults aged 65 years or older.
The high cost of treating hepatitis C with sofosbuvir (Sovaldi) has received a lot of attention in the literature.
Latest Issues
$auto_registration$